All amounts are in US dollars
QUEBEC CITY, June 8 /CNW Telbec/ - AEterna Zentaris Inc. (NASDAQ: AEZS;
TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and
oncology, today reported that after regaining from Ardana Biosciences Ltd.
("Ardana"), the worldwide rights to the growth hormone secretagogue ("GHS") /
ghrelin agonist, AEZS-130, it has entered into an agreement with the
administrators of Ardana to acquire all Ardana assets relating to AEZS-130 for
$232,000. These assets include development data, inventory of compound,
regulatory authorizations, including IND and orphan drug status as a
diagnostic test granted in the United States, as well as a patent application
protecting the use of AEZS-130 for the diagnostic of growth hormone secretion
Ardana had developed AEZS-130 up to the initiation of Phase 3 clinical
trials in the United States for use as an oral diagnostic test of growth
hormone secretion deficiency. In addition to the diagnostic indication,
AEZS-130, based on results of Phase 1 studies conducted by Ardana, has
potential applications for the treatment of cachexia, a condition frequently
associated with severe chronic diseases such as cancer, Chronic Obstructive
Pulmonary Disease and AIDS.
"We are pleased to gain access to a project in an advanced development
stage," said Juergen Engel, Ph.D., President and CEO of AEterna Zentaris. "Our
product portfolio is now complemented with an additional project in Phase 3
clinical trials. We are confident that we can retain the interest of potential
strategic partners for this project as we have already initiated partnering
AEZS-130 Poster Presentation at ENDO
The poster #P2-749 entitled, "Use of an oral GHS ghrelin-mimetic GHS as a
simple diagnostic test for adult GH deficiency", G.R. Merriam, K.C.J. Yuen, P.
Asberry, .V Bonert, A. Dobs, J.M. Garcia, M. Kipnes, M. Kletke, M. Molitch, R.
Swerdloff, C. Wang, D. Cook and B.M.K. Biller, presents the first clinical
data relating to the use of AEZS-130 as a simple diagnostic test for adult
growth hormone deficiency. Data showed that in adult growth hormone deficient
patients, the responses to the orally administered AEZS-130 compound were
comparable to currently validated agents and cleanly separated patients from
normal control subjects.
The poster will be presented at the annual meeting of the Endocrine
Society on Thursday, June 11, 2009, in the Halls A&B of the Walter E.
Washington Convention Center, in Washington, DC.
About AEterna Zentaris Inc.
AEterna Zentaris Inc. is a global biopharmaceutical company focused on
endocrine therapy and oncology, with proven expertise in drug discovery,
development and commercialization. News releases and additional information
are available at www.aezsinc.com.
This press release contains forward-looking statements made pursuant to
the safe harbor provisions of the U.S. Securities Litigation Reform Act of
1995. Forward-looking statements involve known and unknown risks and
uncertainties, which could cause the Company's actual results to differ
materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of the Company to take advantage of business
opportunities in the pharmaceutical industry, uncertainties related to the
regulatory process and general changes in economic conditions. Investors
should consult the Company's quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and
uncertainties relating to the forward-looking statements. Investors are
cautioned not to rely on these forward-looking statements. The Company does
not undertake to update these forward-looking statements, and we disclaim any
obligation to update any such factors or to publicly announce the result of
any revisions to any of the forward-looking statements contained herein to
reflect future results, events or developments except if we are requested to
do so by a governmental authority or applicable law.
For further information:
For further information: Investor Relations: Ginette Vallières, Investor
Relations Coordinator, (418) 652-8525, ext. 265, email@example.com; Media
Relations: Paul Burroughs, Director of Communications, (418) 652-8525, ext.